awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33557040-9508FCC0-6F23-46EE-ACB5-1BE532589BC3
Q33557040-9508FCC0-6F23-46EE-ACB5-1BE532589BC3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33557040-9508FCC0-6F23-46EE-ACB5-1BE532589BC3
Endpoints in phase II trials for advanced non-small cell lung cancer.
P2860
Q33557040-9508FCC0-6F23-46EE-ACB5-1BE532589BC3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33557040-9508FCC0-6F23-46EE-ACB5-1BE532589BC3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
de57c3828a41f59242f253c3cf360fd80d84147d
P2860
Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.